HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance t cell mediated anti-viral immunity

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Kanagavelu, Saravana ^a   Termini, James M ^a   Gupta, Sachin ^a   Raffa, Francesca N ^a   Fuller, Katherine A ^a   Rivas, Yaelis ^a   Philip, Sakhi ^a   Kornbluth, Richard S ^b   Stone, Geoffrey W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BIOTHERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B CELL ACTIVATING FACTOR; CD137 LIGAND; CD70 ANTIGEN; CYTOKINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12P70; LYMPHOCYTE ANTIGEN; PROTEIN GITRL; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; EFFECTOR CELL; FEMALE; HISTOLOGY; HUMAN ADENOVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS REPLICATION;

4-1BB LIGAND; ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; B-CELL ACTIVATING FACTOR; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, ACTIVE; LYMPHOCYTE COUNT; MICE; PROTEIN MULTIMERIZATION; VACCINATION; VACCINES, SUBUNIT; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 84896535932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090100     Document Type: Article

References (75)

1. Reynolds MR, Weiler AM, Piaskowski SM, Piatak M, Jr., Robertson HT, et al. (2012) A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 30: 4465-4475.
2. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, et al. (2012) Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206: 258-266.
3. Cheng C, Wang L, Gall JG, Nason M, Schwartz RM, et al. (2012) Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS One 7: e33969.
4. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
5. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, et al. (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46: 1769-1781. (Pubitemid 351706778)
6. Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, et al. (2008) DNA gag/ adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct Tcell response profiles. J Virol 82: 8161-8171.
7. Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, et al. (2004) Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 78: 7490-7497. (Pubitemid 38915894)
8. Vojnov L, Bean AT, Peterson EJ, Chiuchiolo MJ, Sacha JB, et al. (2011) DNA/ Ad5 vaccination with SIV epitopes induced epitope-specific CD4(+) T cells, but few subdominant epitope-specific CD8(+) T cells. Vaccine 29: 7483-7490.
9. Kaufman DR, Li F, Cruz AN, Self SG, Barouch DH (2012) Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine 30: 506-509.
10. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, et al. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93.
11. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, et al. (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
12. Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, et al. (2013) Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol 87: 1373-1384.
13. Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, et al. (2012) Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One 7: e45840.
14. Barratt-Boyes SM, Soloff AC, Gao W, Nwanegbo E, Liu X, et al. (2006) Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. Journal of General Virology 87: 139-149. (Pubitemid 43056952)
15. Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, et al. (2005) Primeboost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 12: 1769-1777. (Pubitemid 41760289)
16. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 18: 1213-1216. (Pubitemid 38738525)
17. McEnery R (2011) HVTN 505 trial expanded to see if vaccine candidates can block HIV acquisition. IAVI Rep 15: 17.
18. Lee CT, Wu S, Ciernik IF, Chen H, Nadaf-Rahrov S, et al. (1997) Genetic immunotherapy of established tumors with adenovirus-murine granulocytemacrophage colony-stimulating factor. Hum Gene Ther 8: 187-193. (Pubitemid 27089193)
19. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, et al. (2011) Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther 19: 1558-1568.
20. Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, et al. (2011) IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigenspecific CD8+ T cell responses. J Leukoc Biol.
21. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, et al. (2010) Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 120: 607-616.
22. Terabe M, Tagaya Y, Zhu Q, Granger L, Roederer M, et al. (2008) IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells. J Immunol 180: 7276-7286.
23. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, et al. (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113: 5868-5877.
24. Kutzler MA, Weiner DB (2004) Developing DNA vaccines that call to dendritic cells. J Clin Invest 114: 1241-1244. (Pubitemid 40385294)
25. Shedlock DJ, Talbott KT, Cress C, Ferraro B, Tuyishme S, et al. (2011) A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine 29: 6755-6762.
26. Du X, Zheng G, Jin H, Kang Y, Wang J, et al. (2007) The adjuvant effects of costimulatory molecules on cellular and memory responses to HBsAg DNA vaccination. J Gene Med 9: 136-146. (Pubitemid 46444490)
27. Gri G, Gallo E, Di Carlo E, Musiani P, Colombo MP (2003) OX40 ligandtransduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J Immunol 170: 99-106. (Pubitemid 36026128)
28. Liu J, Ostrowski M (2010) Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines. Hum Vaccin 6: 355-359.
29. Ganguly S, Liu J, Pillai VB, Mittler RS, Amara RR (2010) Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. Vaccine 28: 1300-1309.
30. Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, et al. (2012) Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine 30: 691-702.
31. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, et al. (2006) Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 80: 1762-1772. (Pubitemid 43228717)
32. Stone GW, Barzee S, Snarsky V, Spina CA, Lifson JD, et al. (2006) Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol 13: 1223-1230. (Pubitemid 46768880)
33. Bertram EM, Lau P, Watts TH (2002) Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 168: 3777-3785. (Pubitemid 34298377)
34. Bukczynski J, Wen T, Ellefsen K, Gauldie J, Watts TH (2004) Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A 101: 1291-1296. (Pubitemid 38182682)
35. Moraes TJ, Lin GH, Wen T, Watts TH (2011) Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigenspecific CD8 T cells and enhances the duration of protection against influenzainduced respiratory disease. Vaccine 29: 6301-6312.
36. van Olffen RW, Koning N, van Gisbergen KP, Wensveen FM, Hoek RM, et al. (2009) GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol 182: 7490-7500.
37. Nocentini G, Giunchi L, Ronchetti S, Krausz LT, Bartoli A, et al. (1997) A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci U S A 94: 6216-6221. (Pubitemid 27270664)
38. Dolfi DV, Boesteanu AC, Petrovas C, Xia D, Butz EA, et al. (2008) Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells. J Immunol 180: 2912-2921.
39. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, et al. (2000) CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 1: 433-440.
40. Croft M (2003) Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 14: 265-273. (Pubitemid 36693146)
41. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological selftolerance. Nat Immunol 3: 135-142. (Pubitemid 34141443)
42. Rowley TF, Al-Shamkhani A (2004) Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J Immunol 172: 6039-6046. (Pubitemid 38621205)
43. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, et al. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747-1756. (Pubitemid 29272691)
44. Mackay F, Leung H (2006) The role of the BAFF/APRIL system on T cell function. Semin Immunol 18: 284-289. (Pubitemid 44287556)
45. Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML (2010) B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 237: 205-225.
46. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, et al. (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3: e3548.
47. Liu J, Yu Q, Stone GW, Yue FY, Ngai N, et al. (2008) CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 26: 4062-4072.
48. Crouch E, Persson A, Chang D, Heuser J (1994) Molecular structure of pulmonary surfactant protein D (SP-D). Journal of Biological Chemistry 269: 17311-17319. (Pubitemid 24204059)
49. Crouch EC (1998) Structure, biologic properties, and expression of surfactant protein D (SP-D). Biochim Biophys Acta 1408: 278-289. (Pubitemid 28517872)
50. Haswell LE, Glennie MJ, Al-Shamkhani A (2001) Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 31: 3094-3100. (Pubitemid 32994561)
51. Massie B, Mosser DD, Koutroumanis M, Vitte-Mony I, Lamoureux L, et al. (1998) New adenovirus vectors for protein production and gene transfer. Cytotechnology 28: 53-64. (Pubitemid 29188270)
52. Alejo DM, Moraes MP, Liao X, Dias CC, Tulman ER, et al. (2013) An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine. Vaccine 31: 2302-2309.
53. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, et al. (2005) HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 102: 7239-7244. (Pubitemid 40696363)
54. Mattapallil JJ, Douek DC, Buckler-White A, Montefiori D, Letvin NL, et al. (2006) Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 203: 1533-1541. (Pubitemid 43877613)
55. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, et al. (2004) Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78: 2666-2673. (Pubitemid 38314325)
56. Baliga CS, van Maanen M, Chastain M, Sutton RE (2006) Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge. Mol Ther 14: 432-441. (Pubitemid 44184958)
57. Ye Q, Wang L, Wells AD, Tao R, Han R, et al. (2004) BAFF binding to T cellexpressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 34: 2750-2759. (Pubitemid 39430152)
58. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, et al. (2004) B cellactivating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. Journal of Immunology 173: 807-817. (Pubitemid 38924255)
59. Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, et al. (2012) Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 86: 2488-2500.
60. Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, et al. (2011) A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology 8: 48.
61. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, et al. (2013) Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 8: e60031.
62. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, et al. (2013) Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. Journal of Experimental Medicine 210: 743-755.
63. Mims CA (1968) The response of mice to the intravenous injection of cowpox virus. Br J Exp Pathol 49: 24-32.
64. Shacklett BL, Ferre AL (2011) Mucosal immunity in HIV controllers: the right place at the right time. Curr Opin HIV AIDS 6: 202-207.
65. Li Q, Skinner PJ, Ha SJ, Duan L, Mattila TL, et al. (2009) Visualizing antigenspecific and infected cells in situ predicts outcomes in early viral infection. Science 323: 1726-1729.
66. Haase AT (2011) Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 62: 127-139.
67. Picker LJ, Hansen SG, Lifson JD (2012) New paradigms for HIV/AIDS vaccine development. Annu Rev Med 63: 95-111.
68. Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13: 5256-5261. (Pubitemid 47510348)
69. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6: e19499.
70. Palazon A, Teijeira A, Martinez-Forero I, Hervas-Stubbs S, Roncal C, et al. (2011) Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Research 71: 801-811.
71. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, et al. (2005) Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79: 9217-9227. (Pubitemid 40934833)
72. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458: 1034-1038.
73. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10: 11-23.
74. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320: 760-764. (Pubitemid 351929619)
75. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL (2010) HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 5: 428-434.